FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145132954> ?p ?o ?g. }

• W2145132954 endingPage "586" @default.
• W2145132954 startingPage "575" @default.
• W2145132954 abstract "Cyclosporin G (CSG) has produced less nephrotoxicity than cyclosporin A (CSA) at equivalent doses in animal models. Conflicting results have been reported concerning differences in the pharmacokinetics of CSA and CSG in preclinical studies, and no data exist regarding the effect of steady-state oral administration of CSG on renal function in transplant patients or CSG-induced release of endothelin and nitric oxide (NO) in vivo. The objective of the study was to examine steady-state pharmacokinetic profiles of adult renal allograft recipients receiving CSA and CSG in relation to concentrations of endothelin-1 and NO2/NO3 in urine and plasma, creatinine clearance (Clcr), and urinary excretion of N-acetyl-β-D-glucosaminidase (NAG) 9 months after transplantation. Concentrations of CSA and CSG were measured in whole blood over a 12-hour dose interval by both a monoclonal and polyclonal fluorescence polarization radioimmunoassay for CSA. A metabolite fraction was defined as the numerical difference between the levels obtained at each time point by both assays. Patient groups were defined as follows: group 1: initial CSA (n = 6); group 2: initial CSG (n = 7); group 3: five of the seven patients in group 2 taking CSG subsequently undergoing conversion to CSA; group 4: the same five patients in group 3 restudied 1 month after 1:1 dosage conversion to CSA; and group 5: CSA groups 1 and 4 combined (n = 11). In group 1, the metabolite fraction accounted for 32% to 54% of the total measurable drug concentration at each time point, whereas in group 2, the metabolite fraction accounted for at most 10% to 15% of the total drug levels measurable by polyclonal fluorescence polarization radioimmunoassay. Although there were no significant differences in any of the mean pharmacokinetic parameters between groups using monoclonal fluorescence polarization radioimmunoassay, the normalized area under the concentration—time curve (NAUC) value was less in four of five patients after conversion from CSG to CSA, with a more variable and delayed time to reach peak concentration (tmax) but equivalent apparent oral clearance (Clpo) values. Clcr was found to change significantly with time in groups 1 and 5 but not in group 2, with CSA producing a more profound and sustained decrease than CSG. Endothelin-1 and NO2/NO3 levels in plasma and urine remained relatively constant after administration of both CSA and CSG, and there were no significant differences between groups 3 and 4 regarding mean endothelin-1 and NO2/NO3 concentrations in plasma, urinary release of endothelin-1 and NO2/NO3, and mean AUC of endothelin-1 and AUC of NO2/NO3. However, monoclonal NAUC correlated significantly with total urinary endothelin-1 within CSA groups 1 and 5 but not within CSG group 2. Metabolite NAUC correlated significantly with total urinary NAG within CSA group 1. Although limited by the small number of patients, this study suggests that 1) CSG may produce less of a reduction in Clcr over time after oral administration at steady state than does CSA, and 2) this beneficial effect of CSG may be in part due to decreased intrarenal release of endothelin-1, as urinary excretion of endothelin-1 seemed to correlate better with CSA than with CSG exposure." @default.
• W2145132954 created "2016-06-24" @default.
• W2145132954 creator A5009657326 @default.
• W2145132954 creator A5015286481 @default.
• W2145132954 creator A5017258735 @default.
• W2145132954 creator A5019073901 @default.
• W2145132954 creator A5020235583 @default.
• W2145132954 creator A5022111186 @default.
• W2145132954 creator A5029823540 @default.
• W2145132954 creator A5034752588 @default.
• W2145132954 creator A5036512885 @default.
• W2145132954 creator A5071723073 @default.
• W2145132954 creator A5082899242 @default.
• W2145132954 date "1997-07-01" @default.
• W2145132954 modified "2023-10-18" @default.
• W2145132954 title "Comparative Pharmacokinetics and Renal Effects of Cyclosporin A and Cyclosporin G in Renal Allograft Recipients" @default.
• W2145132954 cites W1569540769 @default.
• W2145132954 cites W1826545450 @default.
• W2145132954 cites W1870675304 @default.
• W2145132954 cites W1917435574 @default.
• W2145132954 cites W1953476860 @default.
• W2145132954 cites W1972125397 @default.
• W2145132954 cites W1975366846 @default.
• W2145132954 cites W1975588759 @default.
• W2145132954 cites W1976120009 @default.
• W2145132954 cites W1989569870 @default.
• W2145132954 cites W1990802251 @default.
• W2145132954 cites W1998289175 @default.
• W2145132954 cites W1999680550 @default.
• W2145132954 cites W2002718575 @default.
• W2145132954 cites W2008684260 @default.
• W2145132954 cites W2010358639 @default.
• W2145132954 cites W2017549034 @default.
• W2145132954 cites W2022204458 @default.
• W2145132954 cites W2030745423 @default.
• W2145132954 cites W2031104833 @default.
• W2145132954 cites W2047701086 @default.
• W2145132954 cites W2048925254 @default.
• W2145132954 cites W2055283471 @default.
• W2145132954 cites W2057858527 @default.
• W2145132954 cites W2064855439 @default.
• W2145132954 cites W2066545739 @default.
• W2145132954 cites W2074222070 @default.
• W2145132954 cites W2077700858 @default.
• W2145132954 cites W2078287694 @default.
• W2145132954 cites W2079063592 @default.
• W2145132954 cites W2080314044 @default.
• W2145132954 cites W2080387207 @default.
• W2145132954 cites W2082742583 @default.
• W2145132954 cites W2082851329 @default.
• W2145132954 cites W2089004915 @default.
• W2145132954 cites W2094587228 @default.
• W2145132954 cites W2115226063 @default.
• W2145132954 cites W2115690116 @default.
• W2145132954 cites W2149532658 @default.
• W2145132954 cites W2244258765 @default.
• W2145132954 cites W2418051107 @default.
• W2145132954 cites W2999922885 @default.
• W2145132954 cites W4205860829 @default.
• W2145132954 cites W4232228332 @default.
• W2145132954 cites W4237684431 @default.
• W2145132954 cites W4246017650 @default.
• W2145132954 cites W48637808 @default.
• W2145132954 cites W1973916236 @default.
• W2145132954 cites W2092559091 @default.
• W2145132954 doi "https://doi.org/10.1002/j.1552-4604.1997.tb04339.x" @default.
• W2145132954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9243350" @default.
• W2145132954 hasPublicationYear "1997" @default.
• W2145132954 type Work @default.
• W2145132954 sameAs 2145132954 @default.
• W2145132954 citedByCount "9" @default.
• W2145132954 countsByYear W21451329542014 @default.
• W2145132954 crossrefType "journal-article" @default.
• W2145132954 hasAuthorship W2145132954A5009657326 @default.
• W2145132954 hasAuthorship W2145132954A5015286481 @default.
• W2145132954 hasAuthorship W2145132954A5017258735 @default.
• W2145132954 hasAuthorship W2145132954A5019073901 @default.
• W2145132954 hasAuthorship W2145132954A5020235583 @default.
• W2145132954 hasAuthorship W2145132954A5022111186 @default.
• W2145132954 hasAuthorship W2145132954A5029823540 @default.
• W2145132954 hasAuthorship W2145132954A5034752588 @default.
• W2145132954 hasAuthorship W2145132954A5036512885 @default.
• W2145132954 hasAuthorship W2145132954A5071723073 @default.
• W2145132954 hasAuthorship W2145132954A5082899242 @default.
• W2145132954 hasConcept C112705442 @default.
• W2145132954 hasConcept C126189478 @default.
• W2145132954 hasConcept C126322002 @default.
• W2145132954 hasConcept C126894567 @default.
• W2145132954 hasConcept C159641895 @default.
• W2145132954 hasConcept C2777477808 @default.
• W2145132954 hasConcept C2779528694 @default.
• W2145132954 hasConcept C2780091579 @default.
• W2145132954 hasConcept C2780306776 @default.
• W2145132954 hasConcept C2911091166 @default.
• W2145132954 hasConcept C71924100 @default.
• W2145132954 hasConcept C98274493 @default.
• W2145132954 hasConceptScore W2145132954C112705442 @default.
• W2145132954 hasConceptScore W2145132954C126189478 @default.

• next